Yichang Humanwell Pharmaceutical Co. Ltd. has disclosed morphinan derivatives acting as κ-opioid receptor agonists reported to be useful for the treatment of pain and pruritus.
Shanghai Phrontline Biopharma Co. Ltd. has described antibody-drug conjugates comprising an antibody or antigen-binding fragment targeting HER2 (erbB2) covalently linked to a cytotoxic drug through a linker reported to be useful for the treatment of cancer.
Adlai Nortye Biopharma Co. Ltd. and Adlai Nortye Pte Ltd. have divulged GTPase KRAS (mutant) inhibitors reported to be useful for the treatment of cancer, inflammatory diseases and immunological disorders.
Idorsia Pharmaceuticals Ltd. has identified aryl sulfone and sulfanone derivatives acting as orexin OX2 receptor (HCRTR2) agonists reported to be useful for the treatment of eating disorders, fatigue, Kleine-Levin syndrome, narcolepsy, obesity, pain, and psychiatric and inflammatory disorders, among others.
Inventisbio Co. Ltd. and Inventisbio LLC have synthesized Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.
Samjin Pharmaceutical Co. Ltd. has disclosed inhibitors of 17-β-hydroxysteroid dehydrogenase 13 (HSD17B13; 17-β-HSD 13) and/or estradiol 17-β-dehydrogenase 1 (HSD17B1; 17β-HSD1) and/or HSD17B2 (17β-HSD2). As such, they are believed to be potentially useful for the treatment of nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH).
Pretzel Therapeutics Inc. has described DNA polymerase subunit γ-1 (POLG) modulators reported to be useful for the treatment of neurodegeneration and mitochondrial diseases.
Northridge Health Group (Hong Kong) Co. Ltd. has divulged proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a tyrosine-protein phosphatase non-receptor type 2 (PTPN2; TCPTP) and/or tyrosine-protein phosphatase non-receptor type 1 (PTPN1; PTP-1B)-targeting moiety via a linker.
RSS
